Search - tctmd.com

Displaying 121 - 140 of 232

Sort: Relevancy | Date

News Daily News

Women More Often Than Men Report Lingering Angina After PCI, Raising More Questions

L.A. McKeown

March 06, 2016

News Daily News

Mayor Riesgo de Trombsosis del Dispositivo con Andamiajes Bioabsorbibles Aunque Algunos Riesgos Pueden Mitigarse

Michael O'Riordan

February 23, 2016

News Daily News

Increased Risk of Device Thrombosis With Bioresorbable Scaffold, but Some Say Risks Can Be Mitigated

Michael O'Riordan

February 23, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Industry News

QT Vascular Announces Clinical Outcomes of Its Chocolate Heart Drug Coated Coronary Balloon

January 06, 2016

News Features

Increased Early Risk of Stent Thrombosis With the Absorb Bioresorbable Scaffold

Michael O'Riordan

January 06, 2016

News Daily News

Bioresorbable Scaffolds May Have Role in Spontaneous Coronary Artery Dissections

Todd Neale

December 30, 2015

News Daily News

Residual Dissection After DCB Treatment for De Novo CAD Generally Resolves

Caitlin E. Cox

November 26, 2015

News Features

From Great to Greater: Innovation in Stent Technology Possible, Worth Pursuing

Todd Neale

November 08, 2015

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

News Industry News

Study From China Examines Clinical Outcomes Of Two Drug-Eluting Stents With Bioresorbable Polymers Employing Different Elution And Absorption Rates

October 14, 2015

News Conference News TCT 2015

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

October 14, 2015

News Conference News TCT 2015

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

October 14, 2015

News Conference News TCT 2015

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

October 13, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Conference News TCT 2015

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

News Conference News TCT 2015

Novel Devices Present New Treatment Options for STEMI

Yael L. Maxwell

October 11, 2015

Advertisement

Women More Often Than Men Report Lingering Angina After PCI, Raising More Questions

Mayor Riesgo de Trombsosis del Dispositivo con Andamiajes Bioabsorbibles Aunque Algunos Riesgos Pueden Mitigarse

Increased Risk of Device Thrombosis With Bioresorbable Scaffold, but Some Say Risks Can Be Mitigated

TCTMD’s Top 10 Most Popular Stories for January 2016

QT Vascular Announces Clinical Outcomes of Its Chocolate Heart Drug Coated Coronary Balloon

Increased Early Risk of Stent Thrombosis With the Absorb Bioresorbable Scaffold

Bioresorbable Scaffolds May Have Role in Spontaneous Coronary Artery Dissections

Residual Dissection After DCB Treatment for De Novo CAD Generally Resolves

From Great to Greater: Innovation in Stent Technology Possible, Worth Pursuing

My Takeaways From TCT 2015

Study From China Examines Clinical Outcomes Of Two Drug-Eluting Stents With Bioresorbable Polymers Employing Different Elution And Absorption Rates

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

Novel Devices Present New Treatment Options for STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content